CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
| 0.5948 | |
| 0.5948 | |
| - | |
| 0.5948 | |
| 0.5948 | |
| 0.4007-0.7445 | |
| 7 052 M | |
| 9.9133 | |
| 11 596 M | |
| 31 654 M | |
| 0.0055 | |
| 0.0569 | |
| 0.682 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
AstraZeneca AZN announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disrupt...
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive license agreement with Hong Kong-base...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
